FORM 3

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

| OMB APPROVAL             |               |  |  |  |  |
|--------------------------|---------------|--|--|--|--|
| OMB Number:              | 3235-<br>0104 |  |  |  |  |
| Estimated average burden |               |  |  |  |  |
| hours per                | 0.5           |  |  |  |  |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| Name and Address of Reporting Person*     Davis Krista | 2. Date of E<br>Requiring S'<br>(Month/Day)<br>09/12/202 | tatement<br>/Year)                   | ment ANI PHARMACELITICALS INC [ANIP]                                    |   |              |   |   |  |
|--|--|--------------------------------------|---|---|--------------|---|---|--|
| (Last) (First) (Middle) C/O ANI PHARMACEUTICALS,       |  |                                      | Relationship of Reporting<br>Issuer<br>(Check all applicable)  Director |   |              | 5. If Amendment, Date of Original Filed (Month/Day/Year)  |   |  |
| INC. 210 MAIN STREET WEST                              | _  |                                      | X Officer (give title below) SVP, CHIEF HR                              | Other below)  | (specify     | 6. Individual or Joint/Group Filing (Check Applicable Line)  X Form filed by One Reporting Person |   |  |
| (Street) BAUDETTE MN 56623                             |  |                                      | STI, CIIIZI III   | OTTICE  |              |   | by More than One<br>Person                            |  |
| (City) (State) (Zip)                                   |  |                                      |   |   |              |   |   |  |
| Table I - Non-Derivative Securities Beneficially Owned |  |                                      |   |   |              |   |   |  |
| 1. Title of Security (Instr. 4)                        |  | B                                    | . Amount of Securities<br>Beneficially Owned (Instr.                    | 3. Ownership<br>Form: Direct<br>(D) or Indirect<br>(I) (Instr. 5) |              | 4. Nature of Indirect Beneficial<br>Ownership (Instr. 5)  |   |  |
|  |  | 4                                    | )   |   |              |   | ·   |  |
| (e.g   |  | erivative                            | Securities Beneficia  | (l) (Insti  | r. 5)<br>ned |   |   |  |
| (e.g   |  | erivative<br>s, warran<br>isable and | Securities Beneficia  | (I) (Instruction (II) Own ible sec                                | r. 5)<br>ned | 5.<br>Ownership<br>cise Form:   | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |  |

## **Explanation of Responses:**

## Remarks:

No securities are beneficially owned.

No securities are beneficially owned.

/s/ Krista Davis 09/14/2022

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.